Overview of Network Pharmacology

***Dr. Aditya shah,**
Jr.Resident, Krishna Institute of Medical Sciences, Karad, Maharashtra,
aditya.shah.711@gmail.com
Dr. Mrs. S. A. Jadhav,
Jr.Resident, Krishna Institute of Medical Sciences, Karad, Maharashtra
Dr. Chavda Akshayraj,
Jr.Resident, Krishna Institute of Medical Sciences, Karad, Maharashtra
Dr. Harsh Singh,
Jr.Resident, Krishna Institute of Medical Sciences, Karad, Maharashtra
Dr. Lekhika Singh,
Jr.Resident, Krishna Institute of Medical Sciences, Karad, Maharashtra
Dr. Mrs A. R. Shinde,
Jr.Resident, Krishna Institute of Medical Sciences, Karad, Maharashtra

Abstract:

In terms of security, effectiveness, and long-term viability the one-drug, one-target, one-disease strategy for medication development is currently experiencing numerous difficulties. In recent years, network biology and polypharmacology strategies have become more popular as methodologies for multitarget drug creation and omics integration of information, accordingly. Combining each of these techniques led to the development of an entirely novel framework known as network pharmacology, which examines how medications affect the aforementioned interactome and the diseasome levels. The conventional Indian medical practise known as Ayurveda employs clever compositions with several components and bioactive chemicals; yet, its scientific basis and procedures are still largely unknown. NP techniques acts as a useful tool to comprehend the possible measures, applications, and procedures of the medications. In order to break the medication development deadlock, this section addresses NP and its capacity to investigate conventional health care systems.

Keywords: Network pharmacology, polypharmacology, conventional medicine, pharmacy.

Introduction:

The number of lucrative medicine designs has been steadily declining over the previous 25 years. Over fifty percent of the failures in drug development have occurred during clinical trials as a result of insufficient therapeutic effectiveness and unanticipated hazard [1]. The erroneous driving ethos for medicine creation in classical pharmacology centered around the notion of medicine - an indicator - an illness was firmly suggested as the primary culprit.

Complicated ailments, like diabetes and cancer, etc., frequently occur by the malfunction of a linked entire regulatory network rather than by alteration or malfunctioning of just one molecule. A single molecule functions as a network link in a system. For instance, studies have shown even 7-10% more replication of one specific molecule in the digestive system might result in 70-100% greater yields of the ultimate compound.

According to studies conducted on the malignancy genomic project, a large percentage of abnormalities only occur in a small number of cancerous cells. It is extremely difficult to identify an identical genetic change across specimens. Cancer-related abnormalities will nonetheless primarily be found in genes that are part of particular signalling pathways at the network level. Therefore, the focus on the early detection and treatment of cancer as well as other complicated ailments might not involve just one gene, but rather an exact pathway or network. Thus, it is crucial to analyze illness molecular routes using biological networks. The fusion of bioinformatics with conventional scientific approaches has attracted a lot of anticipation and excitement as the globalization trend and technology enter the broader field of contemporary study. In light of this, [2,3] proposed the idea of network pharmacology (NP). The objective of network pharmacology is to comprehend the pharmacological process of pharmaceuticals from the viewpoint of networks.

Network Pharmacology

Hopkins first used the phrase "network pharmacology" in 2007, and it relies on the notion that many highly effective medications operate on multiple receptors instead of one specific target. [2] NP a new field of study aims to comprehend the mechanism of action and conjugations of drugs with many receptors. [2] The meticulous cataloguing of a medication fragment's chemical connections within an organism's tissue makes utilization of computing capability. According to some reviews [4,5], NP emerged as a key tool for comprehending the intricate connections involving herbal remedies and all parts of the body. By enabling impartial exploration of prospective regions of interest, it also seeks to identify novel medication approaches and objectives and adapt current pharmaceutical compounds for various therapy diseases [6]. To choose the appropriate domains and fresh therapeutic component frameworks, such attempts need to have direction. Conventional wisdom can be quite useful in the endeavor of formulating new pharmaceuticals and reusing those that already have evolved. The forthcoming class of versatile medications may be deliberately designed by merging biology system insights with NP advancements [8, 3, 7].

Purpose of NP

With roots in pharmacy, structure life sciences, ecology, genomics, mathematical biology, and a variety of relevant scientific fields, NP is a multifaceted area of study. It constitutes a network-based discipline specifically, comparable to previously recently announced emerging disciplines [9]. Understanding the chain of connections involving biological entities and medications that alter conventional or pathological enzymatic performance is the primary goal of integrative pharmacology.

Several topics are included in the realm of NP:

- Hypotheses, computations, simulations, and applications of NP.
- Lattice creation and communications divination.
- Hypotheses and techniques on circumstances, optimization, and oversight of the pharmaceutical connections (in this instance typically referred to as an illness system, sickness-sickness web, infection-medication web, medication-target system, structure targets - sickness, as well as medication targets - ailments system, etc.).
- Framework development and collaboration forecasting.

Fundamental Ideas:

The NP school of thought is based on a minimum of 2 fundamental tenets: [10,11,12,13,14]

(1) Physiological energy expenditures continually preserve equilibrium across the course of evolution as long as there aren't any substantial perturbations, or they regulatorily minimize the deliberate exclusion towards the stationary norm. [10] According to computational life sciences, ecological networking (such as the human genome) that has reached its level of stability or optimal balance has reached an ideal condition, meaning it is an intact system with a particular geometrical architecture and particular networking attributes. The diseased or illness condition, or an unsteady network with variable topographical architecture and system attributes, results from disruption or destruction of the network stability. Particular's goal in treating an illness is to bring the physiological system back into harmony or stability or to lessen the extent to which stability has been lost. [11,12]

(2) The idea of Le Chatelier's concept implies that a powerful drug's function is to move the equilibrium in a way that is going to diminish any alteration which has occurred in the structure's (network's) equilibrium (health condition) as a result of a shift (to an unhealthy condition). According to some estimations, a successful drug's position is to trigger a slightly distinct physiological system known to can ensure the functioning of the core performance of an ideal physiological system, if the typical equilibrium can't be effortlessly accomplished, owing to organic duplication (e.g., the duplication of anabolism/atom/retort/reciprocity, etc.), a phenomenon that is a byproduct from organic growth.

The notion of system ecology and physiological equilibrium serves as the foundation for NP, which offers fresh approaches to both the search for novel medications and an awareness of how they function. According to the theory of network pharmacology, we ought to examine hazardous networks instead of merely the genomes. [13,14]

Development from Network Biodiversity to NP

The establishment of extremely successful large data analysis tools presents novel possibilities for the creation of additional exciting and potent screening and treatment approaches [15,16]. It is crucial to comprehend the way that the amino acids obstruct the intricate governing equipment's ability to perform [17]. Research led to the formation of

network biological processes, which contends that broad laws govern networks of life and offer an original conceptual structure that subsequently alters our knowledge of the pathophysiology of pathologies. The link between the genetic makeup and phenotypes for illnesses has been explored using algorithms, notably fact-based, in a number of methods aimed at the creation of regulation frameworks [18].

Single-protein targeting is unsuccessful in addressing complex illnesses, according to collaborative science breakthroughs [19]. The idea of polypharmacology, which pharmaceutical scientists originally perceived as an ineffectual strategy that required to be eliminated in order to build a workable diverse-target medication, was thus made clear to them [20]. Network pharmacology's debut as a stand-alone approach has led to a significant shift away from highly specialized single-target pharmaceuticals and towards multi-targeted medications. In numerous facets of well-being, complex ecology and polypharmacology were integrated in the ensuing decades [21].

NP and Ancient Healing

Methods of investigation for developing novel drugs are increasingly using network-based approaches. By using organic materials as the primary molecule liable for pharmaceutical collaboration and combinatorial hustle and bustle, they aid in understanding novel therapies. These approaches have been demonstrated to be effective in a number of botanical remedies utilized in conventional healing [22,23].

A contemporary method for locating pharmaceutical substances and potential molecules of interest in a large range of botanical formulas or basic botanicals is network pharmacology [24]. This comprehensive method serves as a benchmark for the very first investigation of beneficial substances found in botanical products as well as a fresh curative idea for future research on chemical agents found in pharmacologic pathways in the management of ailments [25,26]. Network pharmacology will therefore provide distinctive and fresh possibilities for identifying active substances, indicators, and the theoretical foundations of conventional healing predicated on the intricate cellular structures of the body of an individual [25,27,28].

NP Applications:

Regarding a cutting-edge strategy for developing medicines, NP is gathering momentum. This method of utilizing computational information is quickly gaining popularity because it is both economical and moderately predictable. As a result, network evaluation offers a wide range of uses and bright prospective possibilities in the procedure of finding and developing new drugs. The key uses of NP are as follows:

a) Pharmacology:

- To create novel markets for organic goods
- Having a grasp of how medications work
- Identifying potential medication complications
- Speculating about future signs

- Calculating hazard
- Analyzing potential associations between drugs
- Medications developed rationally using a collection of interrelated amino-acids
- Utilising drugs

b) **Traditional Medicine**

- There is evidence-based backing for using the medicine of Ayurveda.
- Recognizing the justifications behind standard approaches
- Having a comprehension of how herbal remedies work
- The beneficial effects and security of herbal remedies
- Alternatives to potentially-endangered medicinal plants
- Botanical compositions are designed and prescribed using a system of connections.
- Analyzing several biological agents and examining their combined impact
- Diagnostic indicators from plants for reliability assurance

c) Drug Research

- Discovering new medication sites
- Duration and expense savings from in silico testing
- Knowing about the illness categories' signalling pathways
- Creating tests with aims and medications in mind
- Treatments for illnesses with many genes
- Finding genes that cause illnesses
- Biomarkers detection
- Researching medication or antimicrobial resistance

Loopholes

Pharmaceutical investigation benefits from NP, which aids in the resurgence of conventional wisdom. Even said, there are several drawbacks to utilizing NP to investigate conventional medical care that we can only anticipate can be overcome in the near term.

The followings are the main drawbacks and potential remedies:

1) NP presently uses a variety of resources for chemical extraction and library searches. Despite being well-controlled, archives may contain errors since there is a multitude of forms for understanding, theories, and empirical pieces of information. Additionally, the elements of herbs that go through specific preparation processes throughout the creation of the medication might have experienced chemical alterations as a result of the processes, such as simmering, acid/alkaline responses, correlations with other biological agents, etc.
2) When extrapolating computational and genomics information for both in vivo and in vitro experiments, one must take into account the incorporation, dispersion, metabolic processes, elimination, and hazardous impact characteristics affiliated with the articulation/bioactive when these substances are supplied in the original packaging of the prescription. Regarding this, one can rely on computational technologies that

provide the forecast of such variables. However, conventional prescription drugs typically come with an apparatus for transporting the medication.

3) In light of the scarcity of resources with freely accessible content, recognizing targets typically requires a handful of resources. Sometimes, this can produce outcomes that are insufficient. Additionally, there can be undiscovered prospective targets that are a component of the bioactives' pathway of activity.
4) Many conventional drugs work by targeting a variety of bioactive. In herbal medicines, resonance aids in balancing out the potentially severe pharmaceutical impacts of distinct bioactive. Conventional medicine places a great deal of importance on the relationship of bioactive with numerous specific proteins, their incorporation into the human system following potential protease breakdown, their distribution, and ultimately their pharmacological impact (Gilbert and Alves, 2003). Nonetheless, laboratory methods or in vitro, experiments are inadequate to provide a precise understanding of every relationship that takes place in alive creatures.
5) A wide range of bioactive is the target for numerous standard drugs. Synergy helps medicinal products balance away the possible negative pharmacological effects of various bioactive. The interaction of bioactive with various particular amino acids, their assimilation into the body's immune body after probable proteolytic disintegration, their dispersion, and eventually their pharmaceutical influence is all given significant weight in traditional health care [29]. However, experimental techniques or in vitro, investigations are insufficient to offer an exhaustive grasp of all communication that exists in living things.

Conclusion:

Network pharmaceutical research offers a vast array of opportunities for examining conventional wisdom in search of answers to present-day issues confronting the pharmaceutical development sector. The development of reasonable formulations, the identification of novel drugs, and medication repositioning can all benefit from NEP. Numerous bioactive target permutations have undergone testing. Depending on the component biological agents of conventional medical compositions, data analysis utilizing NP reveals knowledge about how these medications work. This particular type of backward method uses current, combined science to infer the cellular mode of action of compositions. The investigations that were previously done and the research that is currently accessibly served as the foundation for the present-day network assessment. As a result, the statistics are equivocal, as are several investigations. Ongoing and new information is being produced regularly. This strategy is nonetheless advantageous notwithstanding its drawbacks since it sheds light on the secret understanding of our long-forgotten indigenous medicinal expertise. With the use of NP, this understanding may be logically analyzed in order to better comprehend it and come up with innovative remedies for pressing pharmaceutical issues.

References:

1. Kola I, Landis J. 2004. Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery,3(8): 711-71.
2. Hopkins AL. 2007. Network pharmacology. Nature Biotechnology, 25(10): 1110-1111
3. Hopkins AL. 2008. Network pharmacology: the next paradigm in durg discovery. Nature Chemical Biology, 4(11): 682-690.
4. Bo Zhang, Xu Wang, Shao Li, "An Integrative Platform of TCM Network Pharmacology and Its Application on a Herbal Formula, Qing-Luo-Yin", Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 456747, 12 pages, 2013. https://doi.org/10.1155/2013/456747.
5. Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics. 2009 Oct 1;25(19):2466-72. doi: 10.1093/bioinformatics/btp465. Epub 2009 Jul 30. PMID: 19648136; PMCID: PMC2752618.
6. Kibble M, Saarinen N, Tang J, Wennerberg K, Mäkelä S, Aittokallio T. Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products. Nat Prod Rep. 2015 Aug;32(8):1249-66. doi: 10.1039/c5np00005j. PMID: 26030402.
7. Cho D-Y, Kim Y-A, Przytycka TM (2012) Chapter 5: Network Biology Approach to Complex Diseases. PLoS Comput Biol 8(12): e1002820. https://doi.org/10.1371/journal.pcbi.1002820.
8. Ellingson SR, Smith JC, Baudry J. J Comput Chem. 2013; 34:2212. http://dx.doi.org/10.1002/jcc.23367. [PubMed: 23813626]
9. Zhang WJ. 2016c. Network chemistry, network toxicology, network informatics, and network behavioristics: A scientific outline. Network Biology. 2016; 6(1): 37-39.
10. Schilling G, Becher MW, Sharp AH, et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Human Molecular Genetics. 1999;8(3): 397-407.
11. Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M. Drug-target network. Nature Biotechnology. 2007; 25(10): 1119-1126.
12. Janga SC, Tzakos A. Structure and organization of drug-target networks: insights from genomic approaches for drug discovery. Molecular Biosystems. 2009: 5(12): 1536-1548.
13. Barabasi AL, Otlvai ZN. Network biology: understanding the cell's functional organization. Nature Reviews Genetics. 2004; 5(2): 101-113.
14. Chen Y, Zhu J, Lum PY, Yang X, Pinto S, MacNeil DJ, Zhang C, Lamb J, Edwards S, Sieberts SK, Leonardson A, Castellini LW, Wang S, Champy MF, Zhang B, Emilsson V, Doss S, Ghazalpour A, Horvath S, Drake TA, Lusis AJ, Schadt EE. Variations in DNA elucidate molecular networks that cause disease. Nature. 2008 Mar 27;452(7186):429-35. doi: 10.1038/nature06757.
15. Noor, F.; Saleem, M.H.; Aslam, M.F.; Ahmad, A.; Aslam, S. Construction of miRNA-mRNA network for the identification of key biological markers and their

associated pathways in IgA nephropathy by employing the integrated bioinformatics analysis. Saudi J. Biol. Sci. 2021, 28, 4938–4945. [CrossRef]

16. Noor, F.; Noor, A.; Ishaq, A.R.; Farzeen, I.; Saleem, M.H.; Ghaffar, K.; Aslam, M.F.; Aslam, S.; Chen, J.-T. Recent Advances in Diagnostic and Therapeutic Approaches for Breast Cancer: A Comprehensive Review. Cur. Pharm. Des. 2021, 27, 2344–2365. [CrossRef]
17. Bergendahl, L.T.; Gerasimavicius, L.; Miles, J.; Macdonald, L.; Wells, J.N.; Welburn, J.P.; Marsh, J.A. The role of protein complexes in human genetic disease. Protein Sci. 2019, 28, 1400–1411. [CrossRef] [PubMed].
18. Wang, X.; Gulbahce, N.; Yu, H. Network-based methods for human disease gene prediction. Brief. Funct. Genom. 2011, 10, 280–293. [CrossRef] [PubMed]
19. Azmi, A.S.; Wang, Z.; Philip, P.A.; Mohammad, R.M.; Sarkar, F.H. Proof of concept: Network and systems biology approaches aid in the discovery of potent anticancer drug combinations. Mol. Cancer Ther. 2010, 9, 3137–3144. [CrossRef] [PubMed]
20. Anighoro, A.; Bajorath, J.; Rastelli, G. Polypharmacology: Challenges and opportunities in drug discovery: Miniperspective. J. Med. Chem. 2014, 57, 7874–7887. [CrossRef]
21. Ste¸pnicki, P.; Kondej, M.; Koszła, O.; Z˙ uk, J.; Kaczor, A.A. Multi-targeted drug design strategies for the treatment of schizophrenia. Expert Opin. Drug Discov. 2021, 16, 101–114. [CrossRef]
22. Emig, D.; Ivliev, A.; Pustovalova, O.; Lancashire, L.; Bureeva, S.; Nikolsky, Y.; Bessarabova, M. Drug target prediction and repositioning using an integrated network-based approach. PloS ONE 2013, 8, e60618. [CrossRef] [PubMed]
23. Lotfi Shahreza, M.; Ghadiri, N.; Mousavi, S.R.; Varshosaz, J.; Green, J.R. A review of network-based approaches to drug repositioning. Brief. Bioinform. 2018, 19, 878–892. [CrossRef]
24. Yu, G.; Zhang, Y.; Ren,W.; Dong, L.; Li, J.; Geng, Y.; Zhang, Y.; Li, D.; Xu, H.; Yang, H. Network pharmacology-based identification of key pharmacological pathways of Yin–Huang–Qing–Fei capsule acting on chronic bronchitis. Int. J. Chronic Obstr. Pulm. Dis. 2017, 12, 85. [CrossRef]
25. Zhang, Y.-q.; Mao, X.; Guo, Q.-y.; Lin, N.; Li, S. Network pharmacology-based approaches capture essence of Chinese herbal medicines. Chin. Herb. Med. **2016**, 8, 107–116. [CrossRef]
26. Zuo, H.; Zhang, Q.; Su, S.; Chen, Q.; Yang, F.; Hu, Y. A network pharmacology-based approach to analyse potential targets of traditional herbal formulas: An example of Yu Ping Feng decoction. Sci. Rep. **2018**, 8, 1–15. [CrossRef] [PubMed]
27. Li, S. Exploring traditional chinese medicine by a novel therapeutic concept of network target. Chin. J. Integr. Med. **2016**, 22, 647–652. [CrossRef] [PubMed]
28. Zhang W, Chen Y, Jiang H, Yang J, Wang Q, Du Y, Xu H. Integrated strategy for accurately screening biomarkers based on metabolomics coupled with network pharmacology. Talanta. 2020 May 1;211:120710. doi: 10.1016/j.talanta.2020.120710. Epub 2020 Jan 3. PMID: 32070601.

29. Gilbert B, Alves LF. Synergy in plant medicines. Curr Med Chem. 2003 Jan;10(1):13-20. doi: 10.2174/0929867033368583. PMID: 12570718.